PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi+MEKi) therapies have significantly improved clinical outcomes in patients with metastatic melanoma. Unfortunately, the efficacy is beset by the acquisition of drug resistance(1–6). Here we investigated molecular mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hezhe, Liu, Shujing, Zhang, Gao, Wu, Bin, Zhu, Yueyao, Frederick, Dennie T., Hu, Yi, Zhong, Wenqun, Randell, Sergio, Sadek, Norah, Zhang, Wei, Chen, Gang, Cheng, Chaoran, Zeng, Jingwen, Wu, Lawrence W., Zhang, Jie, Liu, Xiaoming, Xu, Wei, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Miao, Benchun, Liu, Jianglan, Song, Claire D., Liu, Jephrey Y., Karakousis, Giorgos C., Schuchter, Lynn M., Lu, Yiling, Mills, Gordon, Cong, Yusheng, Chernoff, Jonathan, Guo, Jun, Boland, Genevieve M., Sullivan, Ryan J., Wei, Zhi, Field, Jeffrey, Amaravadi, Ravi K., Flaherty, Keith T., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891348/
https://www.ncbi.nlm.nih.gov/pubmed/28953887
http://dx.doi.org/10.1038/nature24040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891348/
https://www.ncbi.nlm.nih.gov/pubmed/28953887
http://dx.doi.org/10.1038/nature24040

Ejemplares similares